Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Lakewood-Amedex Biotherapeutics (NAS:LABT) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Lakewood-Amedex Biotherapeutics's EV-to-EBIT for today is
Lakewood-Amedex Biotherapeutics's current Enterprise Value is $7.96 Mil.
Lakewood-Amedex Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.46 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Lakewood-Amedex Biotherapeutics's EV-to-EBITDA for today is:
Lakewood-Amedex Biotherapeutics's current Enterprise Value is $7.96 Mil.
Lakewood-Amedex Biotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.40 Mil.
Lakewood-Amedex Biotherapeutics's current Enterprise Value is $7.96 Mil.
Lakewood-Amedex Biotherapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
Lakewood-Amedex Biotherapeutics's current Enterprise Value is $7.96 Mil.
Lakewood-Amedex Biotherapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.77 Mil.
Lakewood-Amedex Biotherapeutics's current Enterprise Value is $7.96 Mil.
Lakewood-Amedex Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.77 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lakewood-Amedex Biotherapeutics Enterprise Value Related Terms
Lakewood-Amedex Biotherapeutics Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lakewood-Amedex Biotherapeutics Enterprise Value Chart
LABT vs CURX, PBM, NCNA: Enterprise Value Comparison
For the Biotechnology subindustry, Lakewood-Amedex Biotherapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lakewood-Amedex Biotherapeutics Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lakewood-Amedex Biotherapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Lakewood-Amedex Biotherapeutics's Enterprise Value falls into.
Lakewood-Amedex Biotherapeutics Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lakewood-Amedex Biotherapeutics (LABT) has a Enterprise Value of $7.96 Mil as of Jun. 28, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Lakewood-Amedex Biotherapeutics and its competitors.
Is Lakewood-Amedex Biotherapeutics' Enterprise Value too high?
Lakewood-Amedex Biotherapeutics' current Enterprise Value is $7.96 Mil. Overall, Lakewood-Amedex Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Lakewood-Amedex Biotherapeutics' Enterprise Value compare to CURX and PBM?
Lakewood-Amedex Biotherapeutics' Enterprise Value of $7.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Lakewood-Amedex Biotherapeutics and its competitors. Lakewood-Amedex Biotherapeutics's current Enterprise Value is $7.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakewood-Amedex Biotherapeutics stock overvalued right now?
Lakewood-Amedex Biotherapeutics (LABT) has a current Enterprise Value of $7.96 Mil. The current Enterprise Value is $7.96 Mil. Lakewood-Amedex Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Lakewood-Amedex Biotherapeutics (LABT), the current Enterprise Value is $7.96 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lakewood-Amedex Biotherapeutics Business Description
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
8GF Score
Get the complete analysis for LABT
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABT has been successfully added to your 